NCT04551963 2024-10-26
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
BeiGene
Phase 1 Completed
BeiGene
Astellas Pharma Inc
Hutchmed
Ipsen
Jiangsu HengRui Medicine Co., Ltd.
Pfizer
Jiangsu HengRui Medicine Co., Ltd.
Takeda
F2G Biotech GmbH
Millennium Pharmaceuticals, Inc.
AstraZeneca
NIH AIDS Clinical Trials Information Service